Calgent’s
“Operations and R&D Headquarters” was officially inaugurated on Mar 25,
2026. Calgent extended its sincere
gratitude to esteemed officials, honored guests and valued partners for
attending the opening reception, sharing in this special occasion, and offering
their support and guidance.
Guided
by its core vision, Calgent is committed to advancing high-potential drug
candidates to the global market through interdisciplinary integration and
translational medicine. Calgent will
further consolidate its R&D resources and enhance development efficiency,
with plans to initiate an IPO in 2026. Through
robust corporate governance and rigorous R&D management, Calgent aims to
accelerate international strategic partnerships and expand its global presence.